TrialDigestive diseases and sciences2024

Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's Disease.

Sarah Harris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.